Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.73 |
| ▸ | MC1R | Q01726 | 8/20 | 0.73 |
| ▸ | MC5R | P33032 | 3/20 | 0.54 |
| ▸ | MC3R | P41968 | 3/20 | 0.54 |
| ▸ | F12 | P00748 | 4/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12657870 | 1.00 | MC4R (0.73) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL22606146 | 1.00 | MC4R (0.73) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL15127364 | 0.99 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL15127367 | 0.99 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL22605979 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL21392385 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL20362980 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL12657710 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL22606179 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 | |
| SCHEMBL15127368 | 0.98 | MC4R (0.71) | MC4RMC1RMC5RMC3RF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885MC5R 7/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885MC5R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.